Clinical Trials
11
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)โข Click on a phase to view related trials
Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Albireo
- Target Recruit Count
- 52
- Registration Number
- NCT04674761
- Locations
- ๐บ๐ธ
University of California - San Francisco, San Francisco, California, United States
๐บ๐ธJohns Hopkins Hospital, Baltimore, Maryland, United States
๐บ๐ธBoston Children's Hospital, Boston, Massachusetts, United States
Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis
- Conditions
- Progressive Familial Intrahepatic Cholestasis
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Albireo
- Registration Number
- NCT04483531
- Locations
- ๐บ๐ธ
Albireo Pharma Inc., Boston, Massachusetts, United States
A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Albireo
- Target Recruit Count
- 47
- Registration Number
- NCT04006145
- Locations
- ๐บ๐ธ
Hope Clinical Research, Canoga Park, California, United States
๐บ๐ธInland Empire Clinical Trials, LLC, Rialto, California, United States
๐บ๐ธPeak Gastroenterology Associates, Colorado Springs, Colorado, United States
Study of A4250 in Healthy Volunteers Under Fasting, Fed and Sprinkled Conditions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Albireo
- Target Recruit Count
- 17
- Registration Number
- NCT03608319
- Locations
- ๐บ๐ธ
Celerion, Lincoln, Nebraska, United States
This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2
- Conditions
- PFIC2PFIC1
- Interventions
- Drug: A4250 (odevixibat)Drug: Placebo
- First Posted Date
- 2018-06-25
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Albireo
- Target Recruit Count
- 62
- Registration Number
- NCT03566238
- Locations
- ๐บ๐ธ
Children's Hospital Los Angeles, Los Angeles, California, United States
๐บ๐ธUniversity of California, San Francisco, San Francisco, California, United States
๐บ๐ธChildren's Hospital Colorado, Denver, Colorado, United States
- Prev
- 1
- 2
- 3
- Next
News
Ipsen Secures Dual CHMP Approvals for Rare Liver Disease Treatments Following Regulatory Strategy Shift
Ipsen received CHMP approval for odevixibat under the new brand name Kayfanda for Alagille syndrome, marking the second approval for the same drug after rebranding due to orphan status complications.
Madrigal's Resmetirom Shows Promise in NASH Treatment Where Others Have Failed
Madrigal Pharmaceuticals' resmetirom demonstrated significant efficacy in the Phase 3 MAESTRO-NASH trial, achieving both primary endpoints of NASH resolution and liver fibrosis improvement.